Jardiance

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Heart FailureType 2 Diabetes MellitusChronic Kidney DiseaseObesity

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

1

Brethine

Sanofi

Preclinical

12

Amidate

Pfizer

Preclinical

13

Zemplar

AbbVie

Preclinical

—4

Savaysa

Daiichi Sankyo

Preclinical

—5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

46

Xifaxan

SSalix

Preclinical

27

Zoloft

VViatris Specialty LLC

Preclinical

28

Jardiance

Boehringer Ingelheim

Phase 1

39

Coumadin

AAbbott

Preclinical

110

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Type 2 Diabetes Mellitus3 trials

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Completed·Boehringer Ingelheim··NCT02367131·419 enrolled

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Completed·Boehringer Ingelheim··NCT02848833·3,368 enrolled

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Completed·Boehringer Ingelheim··NCT02489942·8,145 enrolled

Heart Failure3 trials

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Completed·Boehringer Ingelheim··NCT05262764·1,200 enrolled

Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure

Completed·Boehringer Ingelheim··NCT05236673·610 enrolled

Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction

Not yet recruiting·Boehringer Ingelheim··NCT07044700·5,000 enrolled

Empagliflozin2 trials

Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT06180109·36 enrolled

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

Completed·Boehringer Ingelheim·Phase 1·NCT07035457·15 enrolled

Allograft1 trial

Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension

Active, not recruiting·OOdense University Hospital·Phase 4·NCT06933355·8 enrolled

Obesity1 trial

Prevention of Progression of Prediabetes, Obesity and CV Risk

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT06446531·64 enrolled

5 more indications

Chronic Kidney Disease1 trial

Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Active, not recruiting·Boehringer Ingelheim··NCT06527846·1,024 enrolled

Atherosclerotic Plaque1 trial

Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)

Withdrawn·UUniversity of Louisville·Phase 4·NCT06280976

Fasting Conditions1 trial

A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions

Not yet recruiting·PPharma Nueva·Phase 1·NCT06308679·28 enrolled

Kidney Disease, Chronic1 trial

A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)

Completed·Boehringer Ingelheim··NCT06287073·299 enrolled

Unspecified1 trial

Regulatory Request NIS in Korea

Completed·Boehringer Ingelheim··NCT03642717·658 enrolled

Details

Drug Info

Related News